149 related articles for article (PubMed ID: 36126175)
1. Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya.
Bourgi K; Ofner S; Musick B; Griffith B; Diero L; Wools-Kaloustian K; Yiannoutsos CT; Gupta SK
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):490-496. PubMed ID: 36126175
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
4. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
5. Unlocking the potential: exploring the impact of dolutegravir treatment on body mass index improvement in underweight adults with HIV in Malawi.
Maphosa T; Dunga S; Makonokaya L; Woelk G; Maida A; Wang A; Ahimbisibwe A; Chamanga RK; Zimba SB; Kayira D; Machekano R
BMC Public Health; 2024 May; 24(1):1321. PubMed ID: 38755632
[TBL] [Abstract][Full Text] [Related]
6. Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study.
Hauser A; Kusejko K; Johnson LF; Günthard HF; Riou J; Wandeler G; Egger M; Kouyos RD
PLoS Med; 2020 Dec; 17(12):e1003397. PubMed ID: 33315863
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy, safety and durability of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: an update on a systematic review and network meta-analysis.
Nickel K; Halfpenny NJA; Snedecor SJ; Punekar YS
BMC Infect Dis; 2021 Feb; 21(1):222. PubMed ID: 33637050
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir in Mexico for special populations: A cost analysis perspective.
Marco B; Cristina H; Cristhian R; Sigfrido R; Del Angel J; Reyes A; Isidoro P
AIDS Rev; 2021 Jul; 23(3):126-132. PubMed ID: 34198310
[TBL] [Abstract][Full Text] [Related]
10. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Virological Outcomes of TB/HIV Coinfected Patients Treated With Dolutegravir-Based HIV Antiretroviral Regimens: Programmatic Experience From Botswana.
Modongo C; Wang Q; Dima M; Matsiri O; Kgwaadira B; Rankgoane-Pono G; Shin SS; Zetola NM
J Acquir Immune Defic Syndr; 2019 Oct; 82(2):111-115. PubMed ID: 31335593
[TBL] [Abstract][Full Text] [Related]
12. Challenges of scale-up to dolutegravir-based regimens in sub-Saharan Africa.
Salou M; Butel C; Comlan AS; Konou AA; Tegueni K; Ehlan A; Lack F; Dossim S; Ayouba A; Delaporte E; Dagnra AY; Peeters M
AIDS; 2020 Apr; 34(5):783-787. PubMed ID: 31895149
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir response in antiretroviral therapy naïve and experienced patients with M184V/I: Impact in low-and middle-income settings.
Ndashimye E; Arts EJ
Int J Infect Dis; 2021 Apr; 105():298-303. PubMed ID: 33722682
[TBL] [Abstract][Full Text] [Related]
14. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of dolutegravir-based antiretroviral therapy in a real-world setting in a Belgian cohort of 4101 HIV patients.
Nasreddine R; Florence E; Vandercam B; Moutschen M; Goffard JC; De Munter P; Delforge M; Marinus W; De Wit S;
AIDS; 2020 Jul; 34(8):1151-1159. PubMed ID: 32287063
[TBL] [Abstract][Full Text] [Related]
16. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
17. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
19. Integrase Strand Transfer Inhibitor Start or Switch Impacts Learning in Women With HIV.
O'Halloran JA; Wang K; Spence AB; Williams DW; Dastgheyb R; Fitzgerald KC; Kamkwalala AR; Maki PM; Sharma A; Gustafson DR; Milam J; Weber KM; Adimora AA; Ofotokun I; Fischl MA; Konkle-Parker D; Lahiri CD; Sheth AN; Xu Y; Rubin LH
J Acquir Immune Defic Syndr; 2021 Apr; 86(5):593-599. PubMed ID: 33394812
[TBL] [Abstract][Full Text] [Related]
20. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
